<?xml version='1.0' encoding='utf-8'?>
<document id="28254951"><sentence text="Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome." /><sentence text="The propensity for CYP3A4 induction by 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999), an irreversible inactivator of myeloperoxidase, was examined in the present study"><entity charOffset="39-125" id="DDI-PubMed.28254951.s2.e0" text="2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide" /><entity charOffset="127-138" id="DDI-PubMed.28254951.s2.e1" text="PF-06282999" /><pair ddi="false" e1="DDI-PubMed.28254951.s2.e0" e2="DDI-PubMed.28254951.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28254951.s2.e0" e2="DDI-PubMed.28254951.s2.e1" /></sentence><sentence text=" Studies using human hepatocytes revealed moderate increases in CYP3A4 mRNA and midazolam-1'-hydroxylase activity in a PF-06282999 dose-dependent fashion" /><sentence text=" At the highest tested concentration of 300 μM, PF-06282999 caused maximal induction in CYP3A4 mRNA and enzyme activity ranging from 56% to 86% and 47% t0 72%, respectively, of rifampicin response across the three hepatocyte donor pools"><entity charOffset="177-187" id="DDI-PubMed.28254951.s4.e0" text="rifampicin" /></sentence><sentence text=" In a clinical drug-drug interaction (DDI) study, the mean midazolam Cmax and area under the curve (AUC) values following 14-day treatment with PF-06282999 decreased in a dose-dependent fashion with a maximum decrease in midazolam AUC0-inf and Cmax of ∼57" /><sentence text="2% and 41" /><sentence text="1% observed at the 500 mg twice daily dose" /><sentence text=" The moderate impact on midazolam pharmacokinetics at the 500 mg twice daily dose of PF-06282999 was also reflected in statistically significant changes in plasma 4β-hydroxycholesterol/cholesterol and urinary 6β-hydroxycortisol/cortisol ratios"><entity charOffset="163-184" id="DDI-PubMed.28254951.s8.e0" text="4β-hydroxycholesterol" /><entity charOffset="185-196" id="DDI-PubMed.28254951.s8.e1" text="cholesterol" /><entity charOffset="209-227" id="DDI-PubMed.28254951.s8.e2" text="6β-hydroxycortisol" /><entity charOffset="228-236" id="DDI-PubMed.28254951.s8.e3" text="cortisol" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e0" e2="DDI-PubMed.28254951.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e0" e2="DDI-PubMed.28254951.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e0" e2="DDI-PubMed.28254951.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e0" e2="DDI-PubMed.28254951.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e1" e2="DDI-PubMed.28254951.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e1" e2="DDI-PubMed.28254951.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e1" e2="DDI-PubMed.28254951.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e2" e2="DDI-PubMed.28254951.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28254951.s8.e2" e2="DDI-PubMed.28254951.s8.e3" /></sentence><sentence text=" Changes in plasma and urinary CYP3A4 biomarkers did not reach statistical significance at the 125 mg three times daily dose of PF-06282999, despite a modest decrease in midazolam systemic exposure" /><sentence text=" Predicted DDI magnitude based on the in vitro induction parameters and simulated pharmacokinetics of perpetrator (PF-06282999) and victim (midazolam) using the Simcyp (Simcyp Ltd" /><sentence text=", Sheffield, United Kingdom) population-based simulator were in reasonable agreement with the observed clinical data" /><sentence text=" Since the magnitude of the 4β-hydroxycholesterol or 6β-hydroxycortisol ratio change was generally smaller than the magnitude of the midazolam AUC change with PF-06282999, a pharmacokinetic interaction study with midazolam ultimately proved important for assessment of DDI via CYP3A4 induction"><entity charOffset="28-49" id="DDI-PubMed.28254951.s12.e0" text="4β-hydroxycholesterol" /><entity charOffset="53-71" id="DDI-PubMed.28254951.s12.e1" text="6β-hydroxycortisol" /><entity charOffset="213-222" id="DDI-PubMed.28254951.s12.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.28254951.s12.e0" e2="DDI-PubMed.28254951.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28254951.s12.e0" e2="DDI-PubMed.28254951.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28254951.s12.e0" e2="DDI-PubMed.28254951.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28254951.s12.e1" e2="DDI-PubMed.28254951.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28254951.s12.e1" e2="DDI-PubMed.28254951.s12.e2" /></sentence><sentence text="" /></document>